New hope for Tough-to-Treat lung cancer patients
Disease control
Recruiting now
This study is testing whether combining two immunotherapy drugs (ES102 and toripalimab) can help control advanced non-small cell lung cancer in patients whose previous treatments have stopped working. The trial will enroll 40 adults with specific types of lung cancer to see how w…
Phase: PHASE2 • Sponsor: Elpiscience (Suzhou) Biopharma, Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC